Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T6517 | Golvatinib | 928037-13-2 | 98% |
|
Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor ... | ||||
T9601 | Tepotinib hydrochloride(1 : x) | 1103508-80-0 | 98% |
|
Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 s... | ||||
T6057 | URMC-099 | 1229582-33-5 | 98% |
|
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)... | ||||
T37596 | Terevalefim | 1070881-42-3 | 98% |
|
Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor. | ||||
T77620 | LMTK3-IN-1 | 2764850-23-7 | 98% |
|
Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway. LMTK3-... | ||||
T6982 | SGI-7079 | 1239875-86-5 | 98% |
|
SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR... | ||||
T11162 | EGFR-IN-8 | 2407957-87-1 | 98% |
|
EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor. | ||||
T77437 | Telisotuzumab | 1781223-80-0 | 98% |
|
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisot... | ||||
T76780 | Onartuzumab | 1133766-06-9 | 98% |
|
Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.Onartuzumab has antitumor activity with inhibitory effects on HGF b... | ||||
T76758 | Rilotumumab | 872514-65-3 | 98% |
Rilotumumab
|
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and ... | ||||
T76743 | Emibetuzumab | 1365287-97-3 | 98% |
Emibetuzumab
|
Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathwa... | ||||
T6154 | SU11274 | 658084-23-2 | 98% |
|
SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2. | ||||
T2054 | Altiratinib | 1345847-93-9 | 98% |
|
Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, c... | ||||
T5656 | (±)-Norcantharidin | 29745-04-8 |
|
|
(±)-Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers. | ||||
T7787 | BMS817378 | 1174161-69-3 | 100% |
|
BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM). | ||||
T4260 | Capmatinib 2HCl | 1197376-85-4 | 100% |
|
Capmatinib 2HCl (INC-280 2HCl) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.Capmatinib 2HCl exhibits picomolar enzymatic poten... | ||||
T5414 | Glumetinib | 1642581-63-2 | 100% |
|
Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM). | ||||
T2208 | Bacitracin Zinc | 1405-89-6 | 63.98% |
|
Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from M... | ||||
T5677 | SAR125884 hydrochlorid (1116743-46-4(free base)) | T5677 | 95% |
|
SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM). | ||||
T67859 | C-Met inhibitor D9 | 299405-67-7 | 97% |
|
C-Met inhibitor D9 is a c-Met kinase inhibitor. |